

Biowaiver for MR products Case study for EU and for ID

Yu San Wu, Boopalan Swaminathan

Prague, 22-23 Sept 2016



Introduction

- Abbott
- Established Pharmaceuticals Product Division (EPD):
 - Branded Generics sold over 130 countries
 - Current focus on Emerging Markets
 - 'Regionalization'
 - Divisional CoP in place






Prague, Sept, 2016



Case study: biowaiver for MR product in EU

- Prolonged release tablet
- Harmonization of formulations (i.e. replacement of formulation)
- No NTI-drug
- Qualitative and quantitative formulations are slightly different
- Grade and source of API other excipients are unchanged
- Manufacturing process and manufacturing site (DE) is the same
- BCS I drug
- Submitted in CH and IT






Composition

Component	Function	Current	Proposed			
Active Substance and Excipients for Tablet Core						
API	Active substance	120.0 mg	120.0 mg			
Microcrystalline cellulose	Filler	13.41 mg	39.4 mg			
Sodium alginate	Drug release matrix	180.0 mg	160.0 mg			
Povidone	Tablet binder	14.11 mg	24.0 mg			
Lactose	Filler	8.47 mg				
Magnesium stearate	Glidant	0.71 mg	1.6 mg			
Water, purified	Moisturizer	23.3 mg	15.0 mg			
Excipients for Film Coating						
Hypromellose	Coating material	2.823 mg	2.45 mg			
Macrogols, type A	Plasticizer		0.63 mg			
Macrogols, type B	Plasticizer		0.42 mg			
Macrogols, type C	Plasticizer	0.483 mg				
Talc	Glidant	4.822 mg	4.20 mg			
Titanium dioxide	Coloring agent	3.449 mg	3.15 mg			
Sunset yellow	Coloring agent	0.182 mg				
wax	Polishing agent		0.15 mg			



Comparative dissolution – pH 1.2




F2= 81, 68 and 80

Prague, Sept, 2016



Comparative dissolution – pH 4.5



RSD too high for F2 \rightarrow multivariate approach (Delta test)* to show equivalence


*Saranadasa H and Krishnamoorthy K (2005) A multivariate test for similarity of two dissolution profiles, *J* Biopharm Statistics 15: 265-278.

Prague, Sept, 2016

Company Confidential © 2016 Abbott 6



Comparative dissolution – pH 6.8



F2= 65, 71 and 67


Prague, Sept, 2016

Company Confidential © 2016 Abbott



7

Comparative dissolution – QC release method



RSD too high for F2 \rightarrow multivariate approach (Delta test)* to show equivalence

*Saranadasa H and Krishnamoorthy K (2005) A multivariate test for similarity of two dissolution profiles, *J* Biopharm Statistics 15: 265-278.

Prague, Sept, 2016



Outcome

- Accepted in IT
- DL received from CH:
 - BCS biowaiver not applicable for MR formulations
 - Answer:
 - Proposed' formulation was previously marketed in CH.
 - Proposed formulation is marketed in several other countries
 - Therefore, no safety concerns
 - \rightarrow Accepted



Prague, Sept, 2016



Emerging markets

- Less harmonization in guidelines (vs EMEA and FDA). KR!
- Communication/Language

표 1 친구율체제((서방성제제 제외) 및 장용성제제에 대한 용출시험조건	more samples	can be used for the test.	BADAN PENGAWAS OBAT DAN MAKANAN REPUBLIK INDONESIA
:, 81 8개세 1) 수용성 제재	아이어에에 에너/ 옷 영향경에서에 대한 영물지점소전 3	Table 1, Dissolution (excl, Sus	n Test Conditions for Orally Administere stained Release Products) and Enteric C	
회전수 (rpm) 50	pH (1) 1.2 (2) 4.0 (3) 6.8 (4) 물 (1)부터 (3)까지의 모든 시혈조건에서 용출시험 음 할 때 규정된 시간 내에 대조약의 평균용출 률이 85% 미만인 경우에는 (1)부터 (3)까지의 시 험에 중 대조약의 평균용출률이 가장 높은 시험 액에서 분당 100회전(100rpm)으로 우가시험을 실시하여야 한다.	1) Water-soluble Product 1) m (1) (2) (3) (4) (4) (5) (2) (4) (5) (4) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5	рН 40	PERATURAN KEPALA BADAN PENGAWAS OBAT DAN MAKANAN REPUBLIK INDONESIA NOMOR HK.03.1.23.12.11.10217 TAHUN 2011 TENTANG OBAT WAJIB UJI EKIVALENSI DENGAN RAHMAT TUHAN YANG MAHA ESA KEPALA BADAN PENGAWAS OBAT DAN MAKANAN REPUBLIK INDONESIA,
2) 난용성제제 난용성제제란 / 을 할 때, 규정 제제를 말한다.	상기 1)중 (1)부터 (4)까지의 모든 시켜고기에니 요소시와 된 시험시간 내에 대조약의 평 了解以下几个概念将有助于		uct duct refers to a product of which the mean of lime when performi	iissolution rate of ng the dissolution
	原创药 (Innovator Product)	: 是指已经过全面的药学	、药理学和毒理学	
	研究以及临床研究数据证实其安	全有效性并首次被批准_	上市的药品。	
	药学等效性(Pharmaceutical e	equivalence): 如果两制剂	含等量的相同活性	
	成分,具有相同的剂型,符合同	同样的或可比较的质量标;	准,则可以认为他	



620


Case Indonesia


- Situation:
 - Product marketed in Indonesia
 - Site transfer from Puerto Rico to Indonesia





- Addition of alternative API supplier
- Extended release formulation
- Two strengths 250 mg ER and 500 mg ER. For both strengths both variations will apply.








Composition ER formulation

	250 mg ER		500 mg ER	
	Unit Formula		Unit Formula	
Ingredients	mg/tablet	%	mg/tablet	%
API	269.1	41 (% core)	538.1	54 (% core)
Hypromellose (rate controlling polymer)	292.5	45 (% core)	300	30 (% core)
Cellulose Microcrystalline	62.4	10 (% core)	50	5 (% core)
Lactose monohydrate			81.9	8 (% core)
Silicon Dioxide	26	4 (% core)	30	3 (% core)
Total (tablet core)	650	100	1000	100
Color coating (non-functional)				
Potassium Sorbate	0.13	0.02 (%tablet)	0.2	0.02 (%tablet)
Opadry II	26	3.79 (%tablet)	40	3.81 (%tablet)
Clear coating (non-functional)				
Potassium Sorbate	0		0.2	0.02 (%tablet)
Opadry	9.75	1.42 (%tablet)	10	0.95 (%tablet)
Total (core + coating)	685.88		1050.2	




Strategy





Comparative dissolution – 250 mg ER

• pH 1.2. F2: 95, 92, and 94




Prague, Sept, 2016

© 2016 Abbott



Comparative dissolution – 250 mg ER

- pH 1.2 (45 min) followed by pH 5.5 (= QC release method)
- F2: 81, 82, and 81




Prague, Sept, 2016



Comparative dissolution – 250 mg ER


• pH 6.8. F2: 92, 94, and 95



Prague, Sept, 2016



Discussion



- Would this approach work in EU?
- What about RoW?




Back-up slides



Comparative dissolution 500 mg ER (for case ID)


• pH 1.2 (F2: 77 – 79)





Comparative dissolution 500 mg ER (for case ID)

• pH 1.2 followed by pH 5.5 (= QC release method). F2: 70-72




Prague, Sept, 2016



Comparative dissolution 500 mg ER (for case ID)

• pH 6.8. F2: 87 - 89





South Korea comp disso - 1

- KR is quite specific about conditions for comparative dissolution
- Different conditions for water soluble products, poorly soluble products, enteric coated (EC), EC with poorly soluble drugs, extended release products
- Example enteric coated product: pH 1.2, pH 6.0, pH 6.8

3) Enteric-coated products

Agitation(rpm)	рН
	(1) 1.2
50	(2) 6.0
	(3) 6.8

When dissolution test is performed under the test condition (2), and the average dissolution of reference drug does not reach 85% within the testing time point specified, an additional test in solution (2) with an agitation by 100 rpm shall be performed.



South Korea comp disso - 2

Acceptance criteria for equivalence of profiles (DR)

- b. When dissolution of the reference drug has a lag time
 - When the average dissolution of the reference drug reaches 85% within 15 min after the lag time: Judged as equivalent if the difference in lag time between the two products is less than 10 min and the average dissolution of the test drug reaches 85% within 15 min after the lag time or the average dissolution of the test drug is within that of the reference drug ± 15 % at around 85%.
 - 2) When the average dissolution of the reference drug reaches 85% at between 15 and 30 min after the lag time: Judged as equivalent if the difference in lag time between the two products is less than 10 min and the average dissolution of the test drug are within that of the reference drug ± 15 % at two appropriate time points when the average dissolution of the reference drug are around 60% and 85%, or the similarity factor(f₂) is not less than 50.
 - 3) Others: Judged as equivalent if the average dissolution of the test drug are within that of the reference drug ± 15 % at two appropriate time points when the average dissolution of the reference drug are around 40% and 85%, or the similarity factor(f2) is not less than 50.
 - Lag time: When dissolution is delayed, it is defined as the time when 5 % of the active pharmaceutical ingredient dissolves and determined by linear interpolation at two appropriate time points when the average dissolution of the reference and test drug are around 5%.



